Produção Nacional
Revisado por pares
Alpha lipoic acid in burning mouth syndrome – a randomized double‐blind placebo‐controlled trial
2009; Wiley; Volume: 38; Issue: 3 Linguagem: Inglês
10.1111/j.1600-0714.2008.00735.x
ISSN1600-0714
AutoresDesirée Rosa Cavalcanti, Fernando Ricardo Xavier da Silveira,
Tópico(s)Glycogen Storage Diseases and Myoclonus
ResumoThe burning mouth syndrome (BMS) is a chronic condition characterized by oral burning pain in the absence of clinical abnormalities and without established therapy. Objectives: The purpose of this study was to evaluate the effectiveness of alpha lipoic acid (ALA) in the management of BMS symptoms through a randomized double‐blind placebo‐controlled trial. Methods: Thirty‐eight patients (34 women and four men, median age 62.9 years, range 36–78) were included and 31 completed the study. The patients were randomized into two cycles of treatment: one with alpha lipoic acid and one with placebo both administered in identical capsules. These cycles were separated by a washout period of 20 days. The oral symptoms and the treatment response were assessed using a 100‐mm visual analog scale before and after each cycle and the global perceived effect score, using a 5‐point scale after each treatment cycle. Results: The level of reduction on burning was significant for both treatments (paired t ‐test: P < 0.05; rp = 0.011; ral < 0.001). Considering the two cycles together, 22 patients reported at least some improvement after ALA use and 23 patients after placebo. Conclusions: Comparison of the oral assessment scores of the two cycles failed to demonstrate the effectiveness of ALA over placebo ( t ‐test: P > 0.05; r = 0.75).
Referência(s)